Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
NCT05953545 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · PHASE2 · withdrawn · last registry update 2024-05-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study closure based on decision of the PI” | – | Registry record, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL10RB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-21Results posted on the registry: EVIVE Biotechnology, F-652 + Placebo (NCT04498377)
- 2023-12-21Also stopped (terminated): EVIVE Biotechnology, F-652 + Placebo (NCT04498377)
- 2023-10-02Also stopped (withdrawn): EVIVE Biotechnology, F-652 + Placebo (NCT05205668)
- 2023-06-13Results posted on the registry: Bristol-Myers Squibb, Pegylated Interferon Lambda-1a + Daclatasvir (DCV) (NCT01866930)
- 2023-06-13Also stopped (terminated): Bristol-Myers Squibb, Pegylated Interferon Lambda-1a + Daclatasvir (DCV) (NCT01866930)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision